Updating clinical endpoint definitions

被引：19
作者：
Hassoun, Paul M. [1 ]
Nikkho, Sylvia [2 ]
Rosenzweig, Erika B. [3 ]
Moreschi, Gail [4 ]
Lawrence, John [4 ]
Teeter, John [5 ]
Meier, Christian [2 ]
Ghofrani, Ardeshir H. [6 ]
Minai, Omar [7 ]
Rinaldi, Paula [8 ]
Michelakis, Evangelos [9 ]
Oudiz, Ronald J. [10 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Bayer Pharma AG, Berlin, Germany
[3] Columbia Univ, New York, NY USA
[4] US FDA, Silver Spring, MD USA
[5] Pfizer Inc, New London, CT USA
[6] Univ Giessen, Giessen, Germany
[7] Cleveland Clin, Cleveland, OH 44106 USA
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Univ Alberta, Edmonton, AB, Canada
[10] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
PULMONARY CIRCULATION | 2013年 / 3卷 / 01期
关键词：
end-points; clinical trials; pulmonary arterial hypertension;
D O I：
10.4103/2045-8932.109920
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The 6-Minute Walk Distance (6-MWD) has been the most utilized endpoint for judging the efficacy of pulmonary arterial hypertension (PAH) therapy in clinical trials conducted over the past two decades. Despite its simplicity, widespread use in recent trials and overall prognostic value, the 6-MWD has often been criticized over the past several years and pleas from several PAH experts have emerged from the literature to find alternative endpoints that would be more reliable in reflecting the pulmonary vascular resistance as well as cardiac status in PAH and their response to therapy. A meeting of PAH experts and representatives from regulatory agencies and pharmaceutical companies was convened in early 2012 to discuss the validity of current as well as emerging valuable endpoints. The current work represents the proceedings of the conference.
引用
收藏
页码：206 / 216
页数：11
相关论文
共 104 条
  • [91] Long-term intravenous epoprostenol infusion in primary pulmonary hypertension -: Prognostic factors and survival
    Sitbon, O
    Humbert, M
    Nunes, H
    Parent, F
    Garcia, G
    Hervé, P
    Rainisio, M
    Simonneau, G
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (04) : 780 - 788
  • [92] Variable impact of combining fatal and nonfatal end points in heart failure trials
    Skali, Hicham
    Pfeffer, Marc A.
    Lubsen, Jacobus
    Solomon, Scott D.
    [J]. CIRCULATION, 2006, 114 (21) : 2298 - 2303
  • [93] Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension
    Soon, Elaine
    Holmes, Alan M.
    Treacy, Carmen M.
    Doughty, Natalie J.
    Southgate, Laura
    Machado, Rajiv D.
    Trembath, Richard C.
    Jennings, Simon
    Barker, Lucy
    Nicklin, Paul
    Walker, Christoph
    Budd, David C.
    Pepke-Zaba, Joanna
    Morrell, Nicholas W.
    [J]. CIRCULATION, 2010, 122 (09) : 921 - U90
  • [94] Health-related quality of life in patients with pulmonary arterial hypertension
    Taichman, DB
    Shin, J
    Hud, L
    Archer-Chicko, C
    Kaplan, S
    Sager, JS
    Gallop, R
    Christie, J
    Hansen-Flaschen, J
    Palevsky, H
    [J]. RESPIRATORY RESEARCH, 2005, 6 (1):
  • [95] Impairment of store-operated Ca2+ entry in TRPC4-/- mice interferes with increase in lung microvascular permeability
    Tiruppathi, C
    Freichel, M
    Vogel, SM
    Paria, BC
    Mehta, D
    Flockerzi, V
    Malik, AB
    [J]. CIRCULATION RESEARCH, 2002, 91 (01) : 70 - 76
  • [96] Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension
    Torbicki, A
    Kurzyna, M
    Kuca, P
    Fijalkowska, A
    Sikora, J
    Florczyk, M
    Pruszczyk, P
    Burakowski, J
    Wawrzynska, L
    [J]. CIRCULATION, 2003, 108 (07) : 844 - 848
  • [97] Assessment of right ventricular function with Doppler echocardiographic indices derived from tricuspid annular motion: comparison with radionuclide angiography
    Ueti, OM
    Camargo, EE
    Ueti, AD
    de Lima-Filho, EC
    Nogueira, EA
    [J]. HEART, 2002, 88 (03) : 244 - 248
  • [98] Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension
    van Wolferen, Serge A.
    Marcus, Johannes T.
    Boonstra, Anco
    Marques, Koen M. J.
    Bronzwaer, Jean G. F.
    Spreeuwenberg, Marieke D.
    Postmus, Pieter E.
    Vonk-Noordegraaf, Anton
    [J]. EUROPEAN HEART JOURNAL, 2007, 28 (10) : 1250 - 1257
  • [99] Ventetuolo Corey E, 2008, Proc Am Thorac Soc, V5, P617, DOI 10.1513/pats.200803-029SK
  • [100] Improvement of von Willebrand factor proteolysis after prostacyclin infusion in severe pulmonary arterial hypertension
    Veyradier, A
    Nishikubo, T
    Humbert, M
    Wolf, M
    Sitbon, O
    Simonneau, G
    Girma, JP
    Meyer, D
    [J]. CIRCULATION, 2000, 102 (20) : 2460 - 2462
234567891011